Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2021 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks: does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago, so that each new instance of essentially the same business is worth more to the company than the last? We need to look for evidence in the transcript. The transcript covers Q3 2021 earnings call. Management discusses various business developments: new contracts, lease agreements, opportunities. We need to see if they explicitly state that the size of new engagements is escalating compared to past ones. Key points from the call: - They mention a new lease with State of New Mexico for a 596-bed facility. That's a specific deal. - They mention an opportunity with Arizona for up to 2,700 beds. That's a potential contract. - They mention Hawaii for a new facility. - They discuss the West Tennessee facility and Leavenworth, but those are expiring contracts. But the question is about successive engagements of the same kind coming in at progressively larger size. For example, are they signing larger contracts now than before? The transcript does not explicitly state that the size of new contracts is larger than historical norms. They talk about specific opportunities, but they don't compare the size of these new deals to past deals in a way that indicates escalation. They mention that the Arizona procurement is for up to 2,700 beds, but they don't say that this is larger than what they used to get. They also mention that they are in discussions for other facilities. There is no statement like "our new contracts are larger than before" or "we are seeing a trend of bigger deals." The management discusses various opportunities but does not frame them as an escalation in unit size. They also mention that they are increasing staffing in anticipation of higher utilization, but that's about volume, not about the size of individual contracts. The question also asks for a comparison against the company's own recent past. The transcript does not provide such a comparison.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.